ITS
InsiderTrading
TradesInsidersCompaniesCluster BuysRankingsAbout
ITS
InsiderTrading Screener

Track SEC Form 4 insider trades. See what corporate insiders are buying and selling.

Browse

  • Trades
  • Insiders
  • Companies
  • Cluster Buys
  • Rankings

Top Insiders

  • Mark Zuckerberg
  • Elon Musk
  • Jamie Dimon
  • Satya Nadella
  • Lisa Su
  • Jensen Huang

Screeners

  • CEO & CFO Purchases
  • Director Purchases
  • Top Buys This Week
  • Top Sales This Week
  • 10b5-1 Trades
  • Buy/Sell Ratios
  • Politician Overlap
  • Sectors

Learn

  • Learn
  • What is a Form 4?
  • About & Methodology
  • What are Cluster Buys?
  • Top Insider Rankings
  • Privacy Policy
  • Terms of Use

Data

  • SEC EDGAR Form 4 ↗
  • CongressStock.com ↗
  • Track13F.com ↗
  • About the data
© 2026 InsiderTradingScreener.com. Data from SEC EDGAR Form 4 filings.For informational purposes only. Not financial advice.
Home / Trades / #454888

Barrett Elizabeth A. bought ALLO

June 18, 2026 · Form 4 insider transaction

Barrett Elizabeth A. bought 95,400 shares of Allogene Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 5 days after the transaction.

Direction
Acquired (buy-side)
Shares
95,400
Price
$0.00
Total value
N/A
InsiderBarrett Elizabeth A.
RoleDirector
CompanyAllogene Therapeutics, Inc. (ALLO)
SecurityRestricted Stock Unit
Transaction codeA — Grant or award
Transaction dateJune 18, 2026
Filing dateJune 23, 2026
Shares owned after95,400
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.

View the original Form 4 on SEC EDGAR